Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$1B |
| 2 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
+$539M |
| 3 |
Alibaba
BABA
|
+$476M |
| 4 |
AGN
Allergan plc
AGN
|
+$464M |
| 5 |
Perrigo
PRGO
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$777M |
| 2 |
Merck
MRK
|
+$766M |
| 3 |
AGN
Allergan Inc
AGN
|
+$573M |
| 4 |
SLB Ltd
SLB
|
+$551M |
| 5 |
TJX Companies
TJX
|
+$521M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.12% |
| 2 | Consumer Discretionary | 14.46% |
| 3 | Technology | 12.11% |
| 4 | Communication Services | 11.75% |
| 5 | Financials | 9.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TUES
451
DELISTED
Tuesday Morning Corp
TUES
| $17.2M | 0.02% |
790,752
+240,618
| +44% | +$4.89M |
|
|
ORBC
452
DELISTED
ORBCOMM, Inc.
ORBC
| $16.8M | 0.02% |
2,574,364
-269,275
| -9% | -$1.69M |
|
|
BLCM
453
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $16.8M | 0.02% |
+75,111
| New | +$16.1M |
|
|
MKTO
454
DELISTED
MARKETO INC COM STK (DE)
MKTO
| $16.3M | 0.02% |
499,419
+242,819
| +95% | +$7.66M |
|
|
ACOR
455
DELISTED
Acorda Therapeutics
ACOR
| $16.2M | 0.02% |
3,305
-194
| -6% | -$833K |
|
456
NN Inc
NNBR
$241M
| $16.2M | 0.02% |
787,322
+115,041
| +17% | +$2.47M |
|
457
IMAX
IMAX
$2.62B
| $16.1M | 0.02% |
520,602
-39,915
| -7% | -$1.17M |
|
458
Marcus & Millichap
MMI
$1.21B
| $16M | 0.02% |
481,501
-23,371
| -5% | -$719K |
|
|
KIN
459
DELISTED
Kindred Biosciences, Inc.
KIN
| $16M | 0.01% |
2,142,466
-90,259
| -4% | -$766K |
|
|
FEIC
460
DELISTED
FEI COMPANY
FEIC
| $15.7M | 0.01% |
174,311
+795
| +0.5% | +$66.3K |
|
|
INXN
461
DELISTED
Interxion Holding N.V.
INXN
| $15.6M | 0.01% |
569,362
-181,847
| -24% | -$4.93M |
|
462
Dorman Products
DORM
$4.3B
| $15.3M | 0.01% |
317,625
-456,638
| -59% | -$21.2M |
|
|
VSLR
463
DELISTED
VIVINT SOLAR, INC.
VSLR
| $15.3M | 0.01% |
+1,654,359
| New | +$18.9M |
|
|
CALA
464
DELISTED
Calithera Biosciences, Inc
CALA
| $14.9M | 0.01% |
+36,900
| New | +$9.64M |
|
465
Prothena Corp
PRTA
$447M
| $14.5M | 0.01% |
700,754
-89,425
| -11% | -$1.87M |
|
466
Warner Bros
WBD
$64.4B
| $14.5M | 0.01% |
420,583
-1,326,451
| -76% | -$46M |
|
|
DISCK
467
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $14.5M | 0.01% |
428,853
-934,789
| -69% | -$31.9M |
|
|
CSLT
468
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $14.4M | 0.01% |
1,229,053
+1,188,582
| +2,937% | +$14.2M |
|
|
ICD
469
DELISTED
Independence Contract Drilling, Inc.
ICD
| $13.6M | 0.01% |
130,374
+8,047
| +7% | +$1.19M |
|
470
Douglas Emmett
DEI
$2.09B
| $12.7M | 0.01% |
447,800
-27,630
| -6% | -$762K |
|
471
Asbury Automotive
ABG
$4.71B
| $12.7M | 0.01% |
167,081
-11,749
| -7% | -$843K |
|
|
MPG
472
DELISTED
Metaldyne Performance Group Inc.
MPG
| $12.4M | 0.01% |
+712,224
| New | +$11.2M |
|
473
ProQR Therapeutics
PRQR
$248M
| $12.4M | 0.01% |
569,958
-60,412
| -10% | -$917K |
|
474
Eagle Bancorp
EGBN
$858M
| $12.2M | 0.01% |
+344,725
| New | +$11.9M |
|
|
AVDL
475
DELISTED
Avadel Pharmaceuticals
AVDL
| $12.2M | 0.01% |
711,507
-776
| -0.1% | -$11.1K |
|
Similar funds
Jennison Associates's Q4 2014 Portfolio in Review
As of Q4 2014, Jennison Associates held 806 positions worth $107B, down 0.8% from $108B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates withdrew a net $3.79B in Q4 2014, closing 91 positions and reducing 351 holdings. Its most notable exit was Oneok, an estimated $184M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 19% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, Jennison Associates opened a new position in Shire pic worth $1B.
- Jennison Associates's largest Q4 2014 buy was Shire pic: 4,721,078 shares worth $1B.
- Jennison Associates added most to Alibaba in Q4 2014, an estimated $476M increase.
- Jennison Associates's biggest Q4 2014 reduction was Alphabet (Google) Class C, cutting an estimated $777M.
- Jennison Associates fully exited Oneok in Q4 2014, selling an estimated $184M.
- Jennison Associates's ten largest holdings make up 20% of its $107B portfolio in Q4 2014.
- Jennison Associates opened 89 new positions and closed 91 in Q4 2014.
- Jennison Associates's portfolio value fell 0.8% quarter-over-quarter to $107B.
Based on Jennison Associates's 13F filing for Q4 2014, filed 6 Feb 2015.